Clinical trials: Schizophrenia Spectrum Disorders
Smoking Cessation, Cigarette Smoking
Treating Smokers With Mental Illness
This is a smoking cessation study that will enroll smokers who have been diagnosed with a severe mental illness. The study will use a combination of intensive tobacco treatment counseling and nicotine replacement therapy to…
- Conditions
- Smoking Cessation, Cigarette Smoking, Schizophrenia, Psychotic Disorders
- Trial name
- NCT03822416
- Testing
- Nicotine patch, Nicotine lozenge, Therapy
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Schizophrenia
The Effects of tDCS on the Neuronal Mechanisms of Cognitive Control in Schizophrenia
The purpose of this study is to better understand the neural correlates of cognitive control (CC) deficits in schizophrenia and determine how these mechanisms can be modulated by transcranial direct current stimulation (tDCS).
- Trial name
- NCT03077347
- Testing
- Transcranial Direct Current Stimulation
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Schizophrenia; Psychosis
Pharmacologic Modulation of Hippocampal Activity in Psychosis
The purpose of this study is to test whether administration of levetiracetam (LEV), a commonly used anti-epileptic that alters neurotransmitter release, can reduce hippocampal hyperactivity.
- Trial name
- NCT04277936
- Testing
- Levetiracetam 500 mg
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Schizophrenia, Bipolar Disorder
Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis
The purpose of this study is to better understand mental illness and will test the hypotheses that, while viewing affective stimuli, patient groups will show increased blood oxygenation level dependent (BOLD) signal by fMRI after…
- Conditions
- Schizophrenia, Bipolar Disorder, Healthy, Psychosis
- Trial name
- GABAmech (NCT04004416)
- Testing
- Lorazepam and fMRI
- Where
- United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Schizophrenia
Relapse Prevention Study in Patients With Schizophrenia
The purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophrenia
- Trial name
- REPRIEVE (NCT01291511)
- Testing
- Iloperidone
- Where
- 63 sites in United States, India and 1 more
- Volunteers
- 635 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia, Smoking Cessation
Varenicline and Smoking Cessation in Schizophrenia
There is a strong association between smoking and schizophrenia with prevalence rates ranging from 74% to 90%, versus a national average of 30% in nonschizophrenic individuals.
- Trial name
- VSCS (NCT01111149)
- Testing
- Sugar Pill, Varenicline, Bupropion HCl
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Minnesota
Schizophrenia
A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia
The purpose of this study is to compare the efficacy of paliperidone palmitate and risperidone long acting injection (LAI) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability…
- Trial name
- NCT00604279
- Testing
- Paliperidone palmitate (R092670), Risperidone
- Where
- 8 sites in China
- Volunteers
- 452 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Schizophrenia and Related Disorders
An Extension Protocol for Patients Who Previously Completed the TMS Pilot Study
This is an open-label extension study to continue to evaluate the safety, tolerability and efficacy of the Repetitive Transcranial Magnetic Stimulation (rTMS) in subjects with schizophrenia or schizoaffective disorder who…
- Trial name
- NCT05526833
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Columbia University
Schizophrenia, Alzheimer Disease
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Single site, parallel-group, double-blind trial of low or high dose of BI 409306 to evaluate the ocular and systemic safety and pharmacokinetics during 14 day treatment period in patients with schizophrenia, Alzheimer's disease…
- Trial name
- NCT02392468
- Testing
- BI 409306 25 mg, BI 409306 50 mg
- Where
- 3 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Schizophrenia, Schizoaffective Disorder
The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.
The purpose of this study is to learn how to help veterans play a stronger role in shaping their mental health care. Specifically we want to see if we can help veterans improve their mental health treatment by helping them decide…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Major Depression
- Trial name
- NCT00466323
- Testing
- Family Member Provider Outreach, Enhanced treatment as usual (e-TAU)
- Where
- 2 sites in United States
- Volunteers
- 238 people
- Sponsor
- US Department of Veterans Affairs
Schizophrenia, Dual Diagnosis
Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?
In this translational research proposal, based on our formulation, we seek to confirm and expand upon data obtained in our pilot study suggesting that cannabis and the cannabinoid agonist dronabinol, given in low dose to patients…
- Conditions
- Schizophrenia, Dual Diagnosis, Psychotic Disorder, Cannabis Use Disorder
- Trial name
- NCT01964404
- Testing
- Marijuana, Dronabinol
- Where
- 2 sites in United States
- Volunteers
- 263 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, Schizoaffective Disorder
Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia
Withania somnifera (WSE; Ashwagandha in Ayurveda) extracts have been used as an adaptogen or to build resistance to stress or diseases in indigenous medical systems in India for centuries.
- Trial name
- NCT01793935
- Testing
- Sensoril®
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- K.N. Roy Chengappa
Schizophrenia
An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia
This is a Phase 3b, 3-year, open-label, multi-center study in which patients with DSM-5 diagnosis of schizophrenia whose current medication(s) is not well tolerated and/or clinical symptoms are not well controlled will be…
- Trial name
- PENNANT (NCT05643170)
- Testing
- Xanomeline and Trospium Chloride Capsules
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Prodromal Schizophrenia, Psychotic Disorders
Psychosis: Early Detection, Intervention and Prevention
The primary aim of this application is to conduct a randomized, controlled clinical trial of a specialized mental health service delivery system specifically developed for prodromal psychotic disorders.
- Conditions
- Prodromal Schizophrenia, Psychotic Disorders, Severe Bipolar Disorder With Psychotic Features, Severe Major Depression With Psychotic Features
- Trial name
- EDIP (NCT01597141)
- Testing
- Family-aided Assertive Community Treatment, Enhanced standard treatment
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- MaineHealth
Schizophrenia, Psychotic Disorders
Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia
The purpose of this study is to compare the effectiveness of two antipsychotic medications, Risperdal® Consta® versus Abilify®, over a 2-year treatment period in the long-term maintenance of patients with schizophrenia.
- Trial name
- NCT00299702
- Testing
- Abilify, Risperidal Consta
- Volunteers
- 355 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Transcranial Direct Current Stimulation, Smoking, Cigarette
tDCS and Cognitive Training Intervention for Chronic Smokers With Schizophrenia
This study is being done to develop new methods to help smokers with schizophrenia to successfully reduce their smoking and/or quit. This is not a treatment study, but will help find new techniques to create better treatments.
- Conditions
- Transcranial Direct Current Stimulation, Smoking, Cigarette, Schizophrenia
- Trial name
- TACTICSS (NCT03588728)
- Testing
- Transcranial Direct Current Stimulation, Cognitive Remediation (CR)
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Pittsburgh
Schizophrenia, Schizoaffective Disorder
Oxytocin and CBSST for People With Schizophrenia
A significant proportion of people with schizophrenia are characterized by impaired ability to socially engage with others, which may reflect social aversion secondary to defeatist beliefs; decreased motivation for social…
- Trial name
- NCT01752712
- Testing
- CBSST + Oxytocin
- Where
- 2 sites in United States
- Volunteers
- 83 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Schizoaffective Disorder
Memantine Augmentation of Targeted Cognitive Training in Schizophrenia
Treatment of schizophrenia currently includes antipsychotic medications and cognitive therapies which improve some symptoms, but do not sufficiently restore cognitive functioning or reduce psychosocial disability.
- Trial name
- NCT04857983
- Testing
- Memantine
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of California, San Diego
Schizophrenia
The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)
This study will test the usefulness of the medication metformin in treating people with schizophrenia or schizoaffective disorder who are overweight and also taking antipsychotic medications.
- Trial name
- METS (NCT00816907)
- Testing
- Metformin
- Where
- 16 sites in United States
- Volunteers
- 146 people
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia
The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes
Approximately 25% of people with schizophrenia abuse marijuana. These people may be using marijuana to self-medicate symptoms such as hallucinations (hearing or seeing things that are not heard or seen by others) or delusions…
- Trial name
- NCT01832766
- Testing
- Dronabinol
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Colorado, Denver